CP-180 Reasons for switching from integrase inhibitors in a real cohort of hiv patients during a 3 year study

• Published in: European journal of hospital pharmacy. Science and practice 2017-03, Vol.24 (Suppl 1), p.A80-A81
• Main Authors: Antonio-Cuscó, M De, Luque, S, González-Colominas, E, Ferrández, O, Monge-Escartin, I, Knobel, H, Salas, E
• Format: Article
• Language: English
• Subjects: Drug interactions
• ISSN: 2047-9956; 2047-9964
• DOI: 10.1136/ejhpharm-2017-000640.178

BackgroundIntegrase inhibitors (INSTIs) are recommended as firstline antiretroviral treatment (ART) in HIV patients. However, several factors such as toxicity, virological failure or a low adherence can lead to a switch of ART.PurposeTo assess the frequency and compare the reasons for switching among the INSTIs in a HIV unit in a tertiary hospital.Material and methodsA retrospective study including all patients who switched from INSTIs to other ART (January 2014–September 2016) in our cohort of 1750 HIV infected patients was conducted. Switches involving ART other than INSTIs were not included. Data collected: demographics, hepatitis C virus coinfection, previous and new ART. Reasons for switching were classified as: adverse events (neuropsychiatric toxicity, dermatologic, gastrointestinal and others), schedule optimisation (convenience, simplification or food restrictions), drug–drug interactions, pregnancy and low level viraemia (LV).Results733 patients were treated with INSTIs during this period: 223 (30.4%) raltegravir, 159 (21.7%) elvitegravir and 351 (47.9%) dolutegravir. The INSTI was switched in 133 patients (7.2% of total patients): 101 (75.9%) men, age 47.0±13.2 years, HCV 39 (29.3%). INSTIs p Value Raltegravir(n=223)Elvitegravir(n=159)Dolutegravir(n=351) Patients switching from INSTI (n=133) 66 (29.6%)40 (25.2%)27 (7.7%)